SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop ...
After banking $78.5 million six months ago, Silverback Therapeutics is back for more. The immuno-oncology biotech is picking up another $85 million to advance its lead antibody-drug conjugate (ADC) ...
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The What: MultiDyne Fiber Optic Solutions has designated IBC2018 as the European debut of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback